Codexis Presents Pre-Clinical Data Highlighting its Programs in Homocystinuria and Maple Syrup Urine Disease at ICIEM 2021
November 22, 2021 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that two of the...
Codexis to Participate in Upcoming Virtual Healthcare Conferences
November 19, 2021 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management...
Codexis Appoints Two New Senior Leaders for Human Resources and Corporate Development
November 15, 2021 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointments...
Codexis to Present Data Highlighting Two New Therapeutic Discovery Programs at the 14th International Congress of Inborn Errors of Metabolism 2021
November 15, 2021 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two oral...
Codexis to Participate in Upcoming Virtual Healthcare Conferences
November 09, 2021 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management...
Codexis Reports Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
Codexis, Inc.
Record Quarterly Total Revenue, Product Revenue and Product Gross MarginReiterating Total Revenue Guidance of $98-103M; Raising Product Revenue Guidance to $63-66M REDWOOD CITY Calif., Nov. 04,...
The SynBio Innovation Accelerator, a Collaboration between Codexis and Casdin Capital, Enables $10 million Investment in Molecular Assemblies, Inc.
November 04, 2021 08:00 ET
|
Codexis, Inc.
Funding to accelerate MAI’s go-to-market strategy as the enzyme engineering phase nears completion Represents the second early-stage company investment enabled by the SynBio Innovation Accelerator ...
Codexis and Nestlé Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
November 03, 2021 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a...
Codexis to Report Third Quarter 2021 Financial Results on November 4
October 21, 2021 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will...
Codexis, Almelo and RC2 Announce a Tri-Party Collaboration for the Enzymatic Production of Low Cost Sitagliptin API for the Generic Market, Including a License to Codexis Enzyme Technology in India
October 18, 2021 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced a tri-party...